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Glutamine synthetase (GS) is a key enzyme in nitrogen
storage and metabolism as it catalyzes the ligation of glu-
tamate and ammonia to glutamine with the help of ATP
[1]. The specific function of GS depends on its localiza-
tion: In astrocytes in brain tissue, GS is part of the gluta-
mate-glutamine cycling, that way detoxifying cytotoxic
ammonia and neurotoxic glutamate by conversion to glu-
tamine; several links between the loss of GS activity and
neurological disorders such as Alzheimer’s disease and
epilepsy have been described. In liver tissue, GS plays an
important role in eliminating ammonia; a loss of GS
activity there leads to hyperammonemia, the main trigger
of hepatic encephalopathy. Two mutations in GS (R324C
and R341C) have been linked to congenital glutamine
deficiency with severe brain malformations resulting in
neonatal death [2]. In a single case known to date,
another GS mutation (R324S) was identified in a boy,
now five years old, who is neurologically compromised
[3]. So far, the molecular mechanisms of these mutations
on GS deactivation have not been understood.
We performed molecular dynamics (MD) simulations of
human wild type GS (wtGS) and the GS mutants R324C,
R324S, and R341C in order to reveal the molecular
mechanisms of GS deactivation. For the wtGS and the
three mutants, four different states each of the enzymatic
process were simulated for a length of 100 ns, resulting in a
total simulation time of 1.6 µs for systems of ~35,000
atoms. In mammals GS is a homodecamer formed by two
pentameric rings, with the active sites located at the inter-
faces between two dimers (Figure 1A, B). To reduce com-
putational costs, we performed the MD simulations on
dimers of GS only. Initial tests on wtGS showed that this
leads to similar structural and dynamics features in the
active site as observed for the decamer.
The MD simulations revealed for each GS mutation a
distinct influence on GS’s highly regulated catalytic
mechanism [4]. According to this mechanism, upon bind-
ing of the co-factor ATP the flexibility of a loop region,
referred to as glutamate flap [4], increases, which enables
binding of glutamate. Next, the terminal phosphate group
of ATP is transferred to the glutamate forming ADP and
the intermediate g-glutamylphosphate (GGP). In this state,
the flap loses its flexibility and seals the active site. This
prevents water from entering and, thus, an early hydrolysis
of GGP, which would lead to a nonproductive catalytic
cycle otherwise. The flap behavior observed in our MD
simulations of wtGS agrees with this mechanism.
The side chain of R324 in wtGS stabilizes in the GGP
bound state the position of the terminal phosphate group
of ADP by a salt bridge (Figure 1C). In contrast, in mutant
R324C, the flap region is highly flexible in all catalytic
stages, leading to a widely open glutamate binding site
even after GGP has been formed, which may result in an
early hydrolysis of GGP. The R324C mutation also leads
to a loss of the direct interaction with ADP, resulting in a
higher mobility of the ligand in the binding pocket. Both
effects can explain the observed loss of GS activity in the
R324C mutant [2]. While the R324S mutation also leads
to a loss of the direct salt bridge interaction with ADP,
this interaction is partially restored by bridging water
molecules in between the sidechain of 324S and the ligand.
This indirect, water-mediated interaction yields a partial
stabilization of the ligand. Nevertheless, the flap’s flexibility
in this state is still higher than in wtGS. As a result, the
ligand is more mobile than in wtGS but not as mobile as
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in the R324C mutant. This can explain why still a residual
activity was observed in the R324S mutant [3].
R341 in wtGS is not part of the catalytic site but is
located close to the surface of GS where it connects two
topologically separated regions. The analysis of the
mechanical stability of these regions by CNAnalysis
(http://www.cnanalysis.de) identified R341 as an import
stabilizing residue. Accordingly, structural distortions in
the neighborhood of the mutation site were observed in
the course of the MD simulations for the R341C mutant.
These structural changes on the surface of GS may explain
the observed loss in affinity for antibody binding to this
mutant [2]. The R341C mutation also exerts a long-range
effect on the GS active site in that the flap loses its
Figure 1 Structure of human GS (PDB entry: 2QC8 [1]) in cartoon representation; (A) top view, (B) side view. Each subunit is colored differently.
(C) Close up view of the active site of human GS with residues R324 (orange) and R341 (magenta), ADP (red), and GGP (blue) shown in sticks
representation and three Mg2+ ions depicted as green spheres. The salt bridge between R324 and ADP is shown as a black dotted line.
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flexibility after ATP binding. This is expected to hamper the
ATP-dependent glutamate binding because the glutamate
binding site is not able to open anymore, which can explain
the observed loss of GS activity in the R341C mutant [2].
In summary, our MD simulations provide detailed
insights into the molecular mechanisms of GS deactivation
by three clinically relevant mutations. The R324C and
R341C mutations exert direct or long-range structural
effects, respectively, that are associated with a complete
loss of GS activity. In contrast, the effect of exchanging
R324 with serine is partially compensated by water-
mediated interactions, resulting in a residual activity of GS.
To date no adequate treatment of a glutamine deficiency
due to GS deactivation is available [3]. Our results allow
suggestions for how to counteract the mutation effects, in
particular in the case of the mutant R324S. On the one
hand, one can aim at overall stabilizing the mutant protein
by changes in the solvent composition adding compatible
solutes. On the other hand, one can aim at restoring origi-
nal interaction strengths between a mutated active site resi-
due and ligands of GS either by noncovalently bound
adaptor molecules or by covalently attached grafting mole-
cules. The latter will result in chemical protein repair.
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